This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Perseus Proteomics Inc., The University of Tokyo. Active years: 2015.
Company Filing History:
1 out of 27 
1 out of 1,355 
Years Active: 2015
Title: The Innovative Contributions of Yoshiko Nakada
Introduction
Yoshiko Nakada is a prominent inventor based in Tokyo, Japan. She has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. Her work has the potential to impact the diagnosis and treatment of malignant tumors.
Latest Patents
Yoshiko Nakada holds a patent for a monoclonal antibody against human GPR87. This invention provides a novel means for diagnosing or treating malignant tumors. The monoclonal antibodies can recognize human GPR87, which is expressed on cell membranes while retaining a three-dimensional structure. They can also recognize GPR87 expressed endogenously, with an epitope present in the extracellular domain of full-length human GPR87. This innovation is useful in biochemical analysis and immunohistological diagnosis of squamous cell carcinoma, and it holds potential for PET diagnosis and treatment of this type of cancer.
Career Highlights
Throughout her career, Yoshiko Nakada has worked with notable organizations, including Perseus Proteomics Inc. and the University of Tokyo. Her experience in these institutions has allowed her to advance her research and contribute to significant scientific advancements.
Collaborations
Yoshiko has collaborated with esteemed colleagues such as Takao Hamakubo and Yasuhiro Mochizuki. These partnerships have fostered a collaborative environment that enhances the quality and impact of her research.
Conclusion
Yoshiko Nakada's innovative work in developing monoclonal antibodies represents a significant advancement in the field of cancer diagnosis and treatment. Her contributions continue to pave the way for future research and applications in biotechnology.